One of the first automatic large scale
segmentation of human brain cortex made by Aliquis®

R&D to enter the AI-first paradigm

We craft machines that unfortunately seem more reliable, fast, and cheap than human beings in decision processes based on vision. Someone call this Artificial Intelligence. Since we believe that many interesting problems can be solved by biologically inspired methods but only when embedded into well-founded theoretical frameworks, in 2012 we founded Bioretics, an innovative company built on more than twenty years of industrial expertise in the field of X-ray medical imaging for automatic cancer detection in mammography. Following the MLOps paradigm, Bioretics today serves as industrial partner for high quality AI-first projects where 2D/3D imaging is the primary data source for extracting high level information. Our focus is maily devoted to 2D, 2.5D and 3D massive real-time image analysis especially when gathered from heterogeneous sources. All codes are always highly optimized to reduce the environmental impact produced by training and deploying AI models.

Discover more
Case history

Launching is easy, operating is hard

Our strength is in the launch phase of new ideas and projects where by leveraging our first-rate Machine Learning framework Aliquis® we are able to go directly from Proof-Of-Concept to prototype in a few weeks. In accordance with MLOps standards, the operational phase is always carried out with industrial partners to whom we guarantee worldwide IPR exclusivity for the developed technology. For business continuity we also provide both Level 2 O&M and source code escrew agreements.


Products and services

We serve customers both with ready-to-use products based on Machine Learning and 2D/3D Computer Vision, as well as with consulting and training services. Successful ideas are turned into assets through patents; commercial rights are protected by trademarks around the world. Scientific dissemination and networking takes place primarily within the EU and the US communities.


Machine Learning lifecycle management

Our team is able to provide end-to-end systems from idea to ready-to-market devices in cooperation with our business partner. We directly participate with our customers in the R&D of new products where efficacy and timing responsiveness are crucial factors for the success on the market. State-of-the-art tools and strong C/C++/CUDA/Python programming skills are coupled into an agile collaborative development environment in order to address every issue in the right way.

  • SIMAI 2020+2021

    Matteo Roffilli invited speaker at SIMAI 2020+2021

    Read more

    Matteo Roffilli invited speaker to the 2nd edition of the CANADA-ITALY Business Forum on AI

    Read more
  • BIORETICS on "Think with GOOGLE"

    Machine Learning: what opportunities for Italian companies?

    Read more
  • Machine Learning sold out? (is there still something to invent?)

    ABSTRACT: Machine Learning sold out? (is there still something to invent?) Machine Learning has no

    Read more
  • Industrial installations
  • Medical installations (classified since 2018)